Mesa Laboratories Inc. (NASDAQ:MLAB) shares moved down -1.01% in last trading session and ended the day at $94.66. MLAB Gross Margin is 61.20% and its has a return on assets of 6.90%. Mesa Laboratories Inc. (NASDAQ:MLAB) quarterly performance is -10.28%.
China Digital TV Holding Co., Ltd. (NYSE:STV) ended the last trading day at $1.98. Company weekly volatility is calculated as 10.20% and price to cash ratio as 1.76. China Digital TV Holding Co., Ltd. (NYSE:STV) showed a weekly performance of 31.13%.
China Digital TV Holding Co., Ltd. (NYSE:STV) the leading provider of cloud-based application platforms and conditional access (“CA”) systems which enable China’s digital cable television market to offer and secure diversified content services, announced that it will hold its annual general meeting (the “AGM”) at 4/F Jingmeng High-Tech Building B, No. 5 Shangdi East Road, Haidian District, Beijing, P.R.C., on Wednesday, December 30, 2015 at 10:00 am
On 28 December, Pool Corp. (NASDAQ:POOL) shares advanced 0.28% and was closed at $82.20. POOL EPS growth in last 5 year was 44.30%. Pool Corp. (NASDAQ:POOL) year to date (YTD) performance is 31.39%.
Pool Corporation (NASDAQ:POOL) announced that James J. Gaffney and George T. Haymaker, Jr. have notified the Pool Corporation Board of Directors (the Board) that they will be retiring from the Board at the end of their current terms. Mr. Gaffney and Mr. Haymaker have been directors of Pool Corporation since 1998 and 2004 respectively, and will not be standing for re-election at the Company’s 2016 annual meeting of shareholders in May 2016.
pSivida Corp. (NASDAQ:PSDV) shares advanced 8.47% in last trading session and ended the day at $4.74. PSDV has a return on assets of -56.30%. pSivida Corp. (NASDAQ:PSDV) quarterly performance is 25.07%.
pSivida Corp. (NASDAQ:PSDV) announced positive topline results from its first Phase 3 clinical trial evaluating the safety and efficacy of Medidur™ for the treatment of chronic noninfectious uveitis affecting the posterior of the eye (posterior uveitis). The 129 patient, multi-center, randomized and double-blinded trial was highly statistically significant in meeting its primary efficacy endpoint of prevention of recurrence of disease at six months (p less than 0.00000001; intent to treat analysis).
Amgen Inc. (NASDAQ:AMGN) caters to the Healthcare space. It has a net profit margin of 30.00% and weekly performance is 1.85%. On the last day of trading company shares ended up at $161.73. Amgen Inc. (NASDAQ:AMGN) distance from 50-day simple moving average (SMA50) is 4.62%.
Amgen (NASDAQ:AMGN) announced that its Board of Directors declared a $1.00 per share dividend for the first quarter of 2016. The dividend will be paid on March 8, 2016, to all stockholders of record as of the close of business on Feb. 16, 2016. This represents a 27 percent increase from that paid in each of the previous four quarters.
Leave a Reply